Answers are grounded in this paper and cite their sources.
The economic burden of BC is well-characterized in the literature. This study suggests that new technologies (i.e., urine-based tests, PDD) and therapeutic regimes (intravesical chemotherapy, adjuvant immunotherapy) have significant potential to improve the diagnosis, treatment and on-going monitoring of BC patients, with potential improvements in clinical outcomes and concurrent cost-savings. A renewed interest and investment in BC research are required to ensure future advancements.
No takes yet. Share an insight, caveat, or question.
Sievert et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: